Back to Search
Start Over
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials
- Source :
- Journal of acquired immune deficiency syndromes (1999). 83(3)
- Publication Year :
- 2019
-
Abstract
- Two-drug regimens (2DRs) can potentially reduce long-term cumulative drug exposure and decrease treatment-associated costs for HIV-1–infected individuals, who require lifelong therapy.1 The core antiretroviral agent in a 2DR must have high potency and a high barrier to resistance.1 As such, early studies investigating 2DRs as initial or maintenance therapy for HIV infection evaluated the pairing of the potent, well-tolerated nucleoside reverse transcriptase inhibitor (NRTI) lamivudine with pharmacologically boosted protease inhibitors (PIs), which have a high barrier to resistance.2–6 Although noninferior efficacy was shown against 3-drug regimens (3DRs), PIs are associated with adverse metabolic effects, long-term toxicities, and drug–drug interactions, limiting their appeal as components of lifelong therapy.7,8 Thus, a need remains for well-tolerated, potent 2DRs with a high barrier to resistance. The integrase strand transfer inhibitor (INSTI) dolutegravir has a high barrier to resistance, making it a well-suited candidate for inclusion in a 2DR,9 particularly when paired with lamivudine,10 as previously observed.11,12 In primary week 48 analyses of the 2 phase III studies GEMINI-1 and GEMINI-2 in treatment-naive adults, dolutegravir + lamivudine was noninferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA
- Subjects :
- Oncology
Adult
Male
medicine.medical_specialty
Adolescent
Anti-HIV Agents
Pyridones
HIV Infections
Emtricitabine
Tenofovir alafenamide
Piperazines
chemistry.chemical_compound
Young Adult
Pharmacotherapy
Maintenance therapy
Acquired immunodeficiency syndrome (AIDS)
Double-Blind Method
Abacavir
Internal medicine
Oxazines
medicine
Humans
Pharmacology (medical)
business.industry
Lamivudine
Middle Aged
medicine.disease
Infectious Diseases
chemistry
Dolutegravir
HIV-1
RNA, Viral
Drug Therapy, Combination
Female
business
Heterocyclic Compounds, 3-Ring
medicine.drug
Subjects
Details
- ISSN :
- 19447884
- Volume :
- 83
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Journal of acquired immune deficiency syndromes (1999)
- Accession number :
- edsair.doi.dedup.....e12488d59ced9e7aed80902e5e729b9d